Sanofi

Activities: Research & Development

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Analysis

UK biotech ends 2025 resilient as investor confidence returns, BIA reports

UK biotech finished 2025 with renewed momentum despite a challenging investment climate, according to the BioIndustry Association, with a strong Q4 rebound and growing policy support boosting confidence as the sector heads into 2026
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

Texas sues Bristol Myers Squibb and Sanofi for the alleged deceptive marketing of Plavix

The State of Texas has filed a lawsuit claiming the drugmakers misled patients and healthcare programmes about Plavix’s effectiveness, particularly for minority populations, risking patient safety
Regulatory

CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU

If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction at 24 weeks
Regulatory

MHRA's approval of Sanofi's Teplizumab signals a new era in type 1 diabetes management

Imagine delaying a life-altering chronic illness. Teplizumab offers precious time, potentially freeing eligible individuals and their families from the immediate and overwhelming demands of T1D
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Distribution

Sanofi ramps up Beyfortus shipping ahead of '25–26 RSV season

Sanofi will boost the availability of the RSV monoclonal antibody vaccine across the US, EU, China and Japan to protect infants from the disease
Subscribe now